AusperBio Raises $120M for Hepatitis B Therapies
AusperBio closed a $120M Series C to advance targeted oligonucleotide therapies for chronic hepatitis B.
AusperBio’s new round shows that biotech investors are still willing to fund expensive clinical paths when the target market is large and the platform is differentiated.
What happened
AusperBio Therapeutics closed a $120M Series C to support its work on targeted oligonucleotide therapeutics for chronic hepatitis B and other diseases.
The round was led by a strategic investor, with RA Capital Management joining as a new investor. Existing backers including HanKang Capital, Sherpa Capital, Qiming Venture Partners, YuanBio Venture Capital and CDH Investments also participated.
The company is developing therapies designed to address chronic hepatitis B, a major global health problem where current treatments can suppress the virus but often do not deliver a functional cure. AusperBio’s approach focuses on targeted oligonucleotide technology, a drug modality that can interfere with disease biology at the RNA level.
The company has now raised $360M since 2024, which points to continued investor conviction rather than a one-off financing.
Why it matters
This is a strong life-sciences signal because the capital is going into a serious clinical and commercial problem, not a vague discovery platform.
Chronic hepatitis B affects a large patient population globally, particularly across Asia. New therapies that can improve durability, safety or cure potential would have meaningful clinical and commercial value.
The strategic investor participation also matters. It suggests AusperBio may be moving closer to the stage where development, regulatory strategy and eventual commercialisation become central, not just early science.
The bigger picture
Biotech funding has become more selective, but large rounds are still available for companies with clear disease targets, credible platforms and near-commercial potential.
For Sam’s lens, this is the healthier side of biotech capital: big money flowing into hard clinical problems where the upside is connected to actual patient need, not just platform storytelling.